| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 196 | 215 | 202 | 196 | 204 | 204 | 210 | 205 | 225 |
| Expenses | 159 | 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 |
| EBITDA | 36 | 40 | 37 | 35 | 37 | 39 | 36 | 27 | 34 |
| Operating Profit % | 18 % | 18 % | 18 % | 18 % | 18 % | 19 % | 16 % | 13 % | 15 % |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 |
| Interest | 4 | 5 | 3 | 4 | 5 | 5 | 5 | 8 | 9 |
| Profit Before Tax | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 17 |
| Tax | 7 | 8 | 7 | 7 | 7 | 8 | 7 | 3 | 4 |
| Net Profit | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 13 |
| EPS in ₹ | 2.13 | 2.39 | 2.23 | 2.00 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 |
Gufic BioSciences
Gufic BioSciences
358.00
-3.55
(-0.98%)
There are new updates from the company1 day ago
View
Market Cap
3,589.90 Cr
EPS
6.95
PE Ratio
57.88
Dividend Yield
0.03 %
Industry
Healthcare52 Week High
504.25
52 Week Low
298.80
PB Ratio
5.96
Debt to Equity
0.63
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Gufic Biosciences Promotes Shekhar Aley to President of Critical Care DivisionSep 16, 2025
Gufic Biosciences Limited promoted Shekhar Tarbir Aley to President - Critical Care SBUs, Nepal & Institution, effective September 16, 2025. Aley was promoted from his previous role as Senior Vice President based on the Board of Directors' approval following the Nomination & Remuneration Committee's recommendation. Aley brings over 30 years of pharmaceutical experience with specialization in Critical Care therapies. He previously led the launch of Prima Care Division to capture critical care business opportunities in smaller Indian towns and has experience building relationships with hospitals across India and Nepal. He holds a B.SC. degree in Pure Science with certifications in people and business management, and is pursuing a Doctorate in Business Administration.
Gufic Biosciences Plans Growth Through Complex Injectables and International ExpansionAug 13, 2025
Gufic Biosciences has outlined its growth strategy focusing on new complex injectables, international market penetration, and Contract Research and Manufacturing Services (CRAMS). The company plans capacity expansion and is developing a strong R&D pipeline to enhance profitability.
Gufic Biosciences reported quarterly results showing revenue growth to 2.3 billion rupees from 2 billion rupees in the same period last year. However, net profit declined to 121 million rupees compared to 208 million rupees in the previous year. EBITDA decreased to 323 million rupees from 358 million rupees, while EBITDA margin compressed to 14.25% from 17.64% in the corresponding period last year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
-11.39 %
Net Income Growth
-16.84 %
Cash Flow Change
-185.26 %
ROE
-35.65 %
ROCE
-56.06 %
EBITDA Margin (Avg.)
2.46 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2024 | 2025 |
| Total Assets | 1,093 | 1,169 |
| Fixed Assets | 159 | 528 |
| Current Assets | 601 | 625 |
| Capital Work in Progress | 307 | 22 |
| Investments | 2 | 217 |
| Other Assets | 625 | 0 |
| Total Liabilities | 1,093 | 1,169 |
| Current Liabilities | 372 | 388 |
| Non Current Liabilities | 188 | 181 |
| Total Equity | 533 | 601 |
| Reserve & Surplus | 523 | 591 |
| Share Capital | 10 | 10 |
Cash Flow
| Cash Flow | 2024 |
| Net Cash Flow | -28 |
| Investing Activities | -102 |
| Operating Activities | -8 |
| Financing Activities | 82 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Oct 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 65.75 % | 65.13 % | 75.48 % | 75.48 % | 75.48 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 72.51 % | 72.51 % | 72.51 % | 72.51 % | 72.51 % | 72.51 % | 72.51 % | 72.51 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.72 % | 0.00 % | 0.12 % | 0.23 % | 0.24 % | 0.30 % | 0.31 % | 0.32 % |
| DIIs | 8.25 % | 3.24 % | 2.13 % | 1.19 % | 1.03 % | 1.03 % | 1.16 % | 1.16 % | 1.16 % | 1.16 % | 1.50 % | 1.58 % | 1.60 % | 2.20 % | 2.39 % | 2.51 % | 2.98 % | 3.39 % | 3.38 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 21.92 % | 27.67 % | 17.00 % | 17.40 % | 17.65 % | 17.84 % | 18.29 % | 18.24 % | 17.83 % | 17.84 % | 17.16 % | 16.66 % | 16.85 % | 16.72 % | 16.36 % | 16.01 % | 15.44 % | 15.15 % | 15.10 % |
| Others | 4.08 % | 3.95 % | 5.39 % | 5.94 % | 5.84 % | 6.13 % | 5.55 % | 5.60 % | 6.01 % | 6.00 % | 6.34 % | 8.53 % | 9.04 % | 8.45 % | 8.52 % | 8.73 % | 8.76 % | 8.64 % | 8.70 % |
| No of Share Holders | 19,639 | 45,602 | 35,135 | 34,580 | 38,144 | 40,120 | 41,376 | 40,562 | 38,902 | 38,624 | 36,557 | 36,524 | 34,424 | 34,695 | 32,250 | 32,825 | 33,299 | 31,844 | 31,876 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.05 | 0.05 | 0.05 | 0.05 | 0.1 | 0.1 | 0.1 | 0.1 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.05 | 0.07 | 0.1 | 0.04 | 0.04 | 0.05 | 0.04 | 0.03 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Sept 2025 |  Annual General Meeting | NA | 29 Sept 2025 | 369.85 | 358.00 |
| 14 Sept 2021 |  Dividend | ₹ 0.10 /share | 09 Sept 2021 | 189.20 | 197.80 |
| 25 Aug 2022 | Dividend | ₹ 0.10 /share | 24 Aug 2022 | 243.75 | 205.20 |
| 21 Sept 2023 | Dividend | ₹ 0.10 /share | 21 Sept 2023 | 207.55 | 285.35 |
| 29 Sept 2023 | Annual General Meeting | NA | 29 Sept 2023 | 308.70 | 286.75 |
| 19 Sept 2024 | Dividend | ₹ 0.10 /share | 17 Sept 2024 | 312.15 | 397.60 |
| 25 Sept 2024 | Annual General Meeting | NA | 25 Sept 2024 | 393.65 | 389.90 |
| 14 Nov 2024 |  Quarterly Result Announcement | NA | 14 Nov 2024 | 473.55 | 437.50 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 426.15 | 406.00 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 380.45 | 390.90 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 364.00 | 354.10 |
| 22 Sept 2025 | Dividend | ₹ 0.10 /share | 22 Sept 2025 | 390.90 | 369.45 |
Announcements
Closure of Trading Window
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
9 days agoPromotion And Re-Designation Of Senior Management Personnel - Mr. Shekhar Tarbir Aley As President - Critical Care Sbus Nepal & InstitutionSep 16, 2025
Sep 16, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 06, 2025
Sep 06, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 05, 2025
Sep 05, 2025Reg. 34 (1) Annual Report.Sep 05, 2025
Sep 05, 2025Intimation Of Record Date For Final Dividend & 41St Annual General MeetingSep 05, 2025
Sep 05, 2025Shareholders Meeting - 41St Annual General Meeting Of The Company Scheduled To Be Held On Monday September 29 2025Sep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 13, 2025
Aug 13, 2025Results - Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2025Aug 13, 2025
Aug 13, 2025Board Meeting Outcome for Meeting Held On Wednesday August 13 2025Aug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 08, 2025
Aug 08, 2025Board Meeting Intimation for Consideration And Approval Of Inter Alia Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Jul 24, 2025Update - Intimation Of Allotment Of Equity Shares Of Gufic Prime Private Limited (Subsidiary Company) Through Rights IssueJul 15, 2025
Jul 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 08, 2025
Jul 08, 2025Appointment Of Senior Management Personnel - Mr. Rajesh Kaul As Senior President - Sparsh ClusterJul 02, 2025
Jul 02, 2025Resignation Of Senior Management PersonnelJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 06, 2025
Jun 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-AcquisitionMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 30, 2025
May 30, 2025Corporate Action-Board approves DividendMay 30, 2025
May 30, 2025Results - Audited (Standalone And Consolidated) Financial Results For The Quarter And Financial Year Ended March 31 2025May 30, 2025
May 30, 2025Board Meeting Outcome for Meeting Held On Friday May 30 2025May 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
May 26, 2025Board Meeting Intimation for Consideration And Approval Of Inter Alia Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended March 31 2025 And To Recommend A Final Dividend If Any For The Financial May 23, 2025
May 23, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Resignation Of Cost AuditorMay 02, 2025
May 02, 2025Updation Of Contact Details Of Registrar And Share Transfer Agent (RTA) Of The CompanyApr 18, 2025
Apr 18, 2025Intimation Of Appeal Filed Against Assessment Order Passed By The Assessment Unit Income Tax DepartmentApr 14, 2025
Apr 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Apr 08, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 21, 2025
Feb 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Feb 20, 2025Technical Indicators
RSI(14)
Neutral 44.24
ATR(14)
Less Volatile 10.91
STOCH(9,6)
Neutral 62.70
STOCH RSI(14)
Neutral 48.51
MACD(12,26)
Bearish -0.24
ADX(14)
Weak Trend 14.78
UO(9)
Bearish 53.50
ROC(12)
Downtrend And Accelerating -3.43
WillR(14)
Neutral -70.64
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 ICICI Prudential Multicap Fund Direct Plan-Growth | 0.20% | 824844 | 0.20% | 0.20% | |
 Motilal Oswal Small Cap Fund Direct - Growth | 0.43% | -800105 | -0.63% | -0.56% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.08% | -2 | 0.00% | 0.01% | |
 Bank of India Business Cycle Fund Direct-Growth | 0.96% | 0 | -0.04% | 0.06% | |
| Bank of India Small Cap Fund Direct-Growth | 0.68% | 0 | -0.03% | 0.02% | |
| ICICI Prudential ELSS Tax Saver Direct Plan - Growth | 0.02% | 0 | 0.00% | 0.00% | |
| ICICI Prudential Regular Savings Fund Direct-Growth | 0.00% | 0 | 0.00% | 0.00% | |
| ICICI Prudential Smallcap Fund Direct Plan-Growth | 0.19% | 0 | -0.01% | 0.00% | |
 SBI Healthcare Opportunities Fund Direct Plan-Growth | 0.93% | 0 | -0.06% | -0.02% | |
 WhiteOak Capital Pharma and Healthcare Fund Direct - Growth | 0.00% | 0 | 0.00% | 0.00% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
